Stocktoria
PROTHENA CORP PUBLIC LTD CO PRTA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-12-21
PROTHENA CORP PUBLIC LTD CO financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $9.7M | $135.2M | $91.4M | $53.9M | $200.6M |
| R&D expense | $134.9M | $222.5M | $220.6M | $135.6M | $82.3M |
| Operating income | -$214.6M | -$154.6M | -$191.0M | -$131.6M | $72.0M |
| Income tax | $43.3M | -$6.6M | -$13.5M | -$8.7M | $4.9M |
| Net income | -$244.1M | -$122.3M | -$147.0M | -$116.9M | $67.0M |
| EPS (diluted) | $-4.53 | $-2.27 | $-2.76 | $-2.47 | $1.38 |
| Operating cash flow | -$163.6M | -$150.1M | -$133.9M | -$108.8M | $92.6M |
| Cash & equivalents | $307.5M | $471.4M | $618.8M | $710.4M | $579.1M |
| Total assets | $326.8M | $547.1M | $696.4M | $758.0M | $609.4M |
| Total liabilities | $46.3M | $60.2M | $135.0M | $136.0M | $143.3M |
| Shareholders' equity | $280.5M | $486.9M | $561.4M | $622.0M | $466.0M |
Source: SEC EDGAR filings · CIK 0001559053 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.